Tirzepatide
- Generic Name
- Tirzepatide
- Brand Names
- Mounjaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2023788-19-2
- Unique Ingredient Identifier
- OYN3CCI6QE
- Background
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...
- Indication
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 40
- Registration Number
- NCT06518837
- Locations
- 🇺🇸
Trinitas Comprehensive Cancer Center, Elizabeth, New Jersey, United States
🇺🇸RWJ Barnabas Health - Robert Wood Johnson University Hospital, Hamilton, Hamilton, New Jersey, United States
🇺🇸RWJBarnabas Health - Cooperman Barnabas, Livingston, Livingston, New Jersey, United States
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 48
- Registration Number
- NCT06517212
- Locations
- 🇺🇸
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared With Tirzepatide Alone in Participants With Obesity Aged 55 Years and Over
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- BioAge Labs, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT06515418
- Locations
- 🇺🇸
Site 110, Mesa, Arizona, United States
🇺🇸Site 103, Montclair, California, United States
🇺🇸Site 107, Los Angeles, California, United States
Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT06485089
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸University of Kansas Medical Center Breast Cancer Prevention Center, Westwood, Kansas, United States
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06445075
- Locations
- 🇺🇸
ProSciento CRU, Chula Vista, California, United States
🇺🇸AdventHealth Translational Research Institute, Orlando, Florida, United States
🇺🇸Great Lakes Clinical Trials, LLC d/b/a Flourish Research, Chicago, Illinois, United States
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT06439277
- Locations
- 🇺🇸
Sutter Valley Medical Foundation (SVMF) Pediatric Endocrinology, Sacramento, California, United States
🇨🇦Premier Clinical Trial Network, Hamilton, Ontario, Canada
🇬🇧Bristol Royal Hospital for Children, Bristol, Bristol, City Of, United Kingdom
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
- Conditions
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 360
- Registration Number
- NCT06373146
- Locations
- 🇺🇸
Hassman Research Institute Marlton Site, Marlton, New Jersey, United States
🇺🇸CTI Clinical Research Center, Cincinnati, Ohio, United States
🇺🇸Velocity Clinical Research, Gardena, Gardena, California, United States
The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.
- Conditions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- CorEvitas
- Registration Number
- NCT06354101
A Study of LY3841136 in Overweight and Obese Participants
- Conditions
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 96
- Registration Number
- NCT06345066
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
- Conditions
- Interventions
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 355
- Registration Number
- NCT06326060
- Locations
- 🇺🇸
Velocity Clinical Res-Dallas, Dallas, Texas, United States
🇺🇸UT Southwestern Medical Center - Lingvay, Dallas, Texas, United States
🇦🇺Paratus Clinical, Herston, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.